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CorCap device in addition to mitral
surgery in heart failure: Is it truly
beneficial?
To the Editor:
The recent report about mitral valve sur-
gery in heart failure1 raises a number of
interesting questions. While left ventricular
(LV) end-diastolic volume and end-systolic
volume in the treatment group decreased
significantly more with the cardiac support
device (CorCap; Acorn Cardiovascular, St
Paul, Minn) than in the control group, other
differences were statistically insignificant.
Important end points such as survival, ejec-
tion fraction, and measurable indices of
functional capacity (6-minute walking test
and oxygen consumption), although pre-
sented as “better” in the treatment group,
were not statistically different. The only
adverse event that was nearing significance
(P  .06) in favor of the control group,
namely a neurologic deficit/stroke, is hid-
den in Table 2. The lack of significant
advantages to the treatment group in the
presence of a similarly stable mitral repair
is intriguing. The CorCap device is envel-
oping both ventricles, defining a new upper
limit to total (end-diastolic) biventricular
volume. We are all familiar with the echo-
cardiographic picture of the spherical shape
of the globally enlarged LV, including the
interventricular septum. Obviously, by en-
veloping both ventricles from the outside,
the device does not restrict or reshape the
septal component of LV dilatation. More-
over, assuming that the tension of the de-
vice is even and equal throughout, this
means that we are expecting to limit LV
free-wall dilatation by suspending it on the
right ventricle (RV). Can we trust the RV
with its much lower pressures and wall
tension to successfully counteract and re-
strict either the systolic or the diastolic
distention of the globally or even the re-
gionally enlarged LV? It is likely that the
greater reduction in LV volumes observed
in the treatment group is the result of a new
balance between the two ventricles. RV
volume is restricted more than LV volume.
The RV being dragged or “squeezed” to-
ward the LV during each systole, and
having decreased space for diastolic fill-
ing because of the rightward bulging, non-
compliant ventricular septum, can now
produce a smaller stroke volume. LV
end-diastolic volume is consequently de-
creased, with some improvement in shape,
but probably with minimal change in wall
stress and ejection fraction beyond what
has already been accomplished with mitral
repair or replacement. The authors con-
clude that in addition to the clear benefit
from elimination of mitral regurgitation,
there is significant additional benefit with
the CorCap device.
The question remains whether the me-
chanical preload reduction of the LV via
RV restriction, which does not improve LV
contractile function, outweighs the adverse
events and the risks and technical difficul-
ties encountered when such a patient re-
quires heart transplantation.
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Microbiologically documented
nosocomial infections after coronary
artery bypass surgery without
cardiopulmonary bypass
To the Editor:
In the latest issue of the Journal of Tho-
racic and Cardiovascular Surgery, we read
with great interest the article by Falagas
and colleagues,1 in which they evaluated
the frequency, characteristics, and predis-
posing factors of microbiologically docu-
mented nosocomial infections in a well-
defined subgroup of critically ill patients
undergoing off-pump coronary artery bypass
grafting. In this clearly and well-documented
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